Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 7/20 | 0.55 |
| ▸ | LIMK2 | P53671 | 7/20 | 0.55 |
| ▸ | TESK1 | Q15569 | 4/20 | 0.55 |
| ▸ | TESK2 | Q96S53 | 4/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19031284 | 0.77 | CSNK2A2 (0.52) | CSNK2A2CSNK2A1ALDH1A1 | |
| SCHEMBL21495082 | 0.74 | RAB9A (0.63) | SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL28518148 | 0.74 | LIMK1 (0.51) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL5999957 | 0.74 | LIMK1 (0.63) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL21495031 | 0.73 | MLYCD (0.50) | LIMK1LIMK2TESK1TESK2MAPK8 | |
| SCHEMBL19031383 | 0.72 | ABL1 (0.44) | HTTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL19281696 | 0.72 | CSNK2A2 (0.44) | CSNK2A2CSNK2A1RAB9A | |
| SCHEMBL6002138 | 0.71 | LIMK1 (1.00) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL6001410 | 0.71 | LIMK1 (0.86) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL21484611 | 0.69 | WNT3A (0.48) | HTTSMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | LIMK1 3672/4885LIMK2 3891/4885TESK1 2936/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | LIMK1 3672/4885LIMK2 3891/4885TESK1 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.